Table 2.
Patient characteristics—metastatic tumours
| Category | Subcategory | mCRC (n = 237) | NET (n = 58) | Breast (n = 47) | Pancreatic (n = 32) | Melanoma (n = 32) | Other liver metastases (n = 79)a | All (n = 485) |
|---|---|---|---|---|---|---|---|---|
| ECOG status | 0–fully active | 140 (59.1%) | 38 (65.5%) | 29 (61.7%) | 20 (62.5%) | 15 (46.9%) | 41 (51.9%) | 283 (58.4%) |
| 1–restricted | 75 (31.6%) | 14 (24.1%) | 16 (34.0%) | 8 (25.0%) | 14 (43.8%) | 32 (40.5%) | 159 (32.8%) | |
| 2 or higher | 18 (7.6%) | 5 (8.6%) | 2 (4.3%) | 3 (9.4%) | 1 (3.1%) | 6 (7.6%) | 35 (7.2%) | |
| Missingb | 4 (1.7%) | 1 (1.7%) | – | 1 (3.1%) | 2 (6.3%) | – | 8 (1.6%) | |
| Extra-hepatic disease | No | 139 (58.6%) | 25 (43.1%) | 17 (36.2%) | 17 (53.1%) | 25 (78.1%) | 33 (41.8%) | 256 (52.8%) |
| Yes | 98 (41.4%) | 33 (56.9%) | 30 (63.8%) | 15 (46.9%) | 7 (21.9%) | 46 (58.2%) | 229 (47.2%) | |
| Ascites | No | 228 (96.2%) | 54 (93.1%) | 44 (93.6%) | 29 (90.6%) | 31 (96.9%) | 75 (94.9%) | 461 (95.1%) |
| Yes | 9 (3.8%) | 4 (6.9%) | 3 (6.4%) | 3 (9.4%) | 1 (3.1%) | 4 (5.1%) | 24 (4.9%) | |
| Cirrhosis | No | 235 (99.2%) | 58 (100%) | 45 (95.7%) | 32 (100%) | 32 (100%) | 77 (97.5%) | 479 (98.8%) |
| Yes | 2 (0.8%) | – | 2 (4.3%) | – | – | 2 (2.5%) | 6 (1.2%) | |
| Location of liver tumours | Bilobar | 158 (66.7%) | 51 (87.9%) | 37 (78.7%) | 23 (71.9%) | 32 (100%) | 56 (70.9%) | 357 (73.6%) |
| Left only | 23 (9.7%) | – | 4 (8.5%) | 1 (3.1%) | – | 5 (6.3%) | 33 (6.8%) | |
| Right only | 55 (23.2%) | 7 (12.1%) | 6 (12.8%) | 8 (25.0%) | – | 18 (22.8%) | 94 (19.4%) | |
| Missing | 1 (0.4%) | – | – | – | – | – | 1 (0.2%) | |
| Number of liver tumours | 1 | 21 (8.9%) | 2 (3.4%) | 7 (14.9%) | 1 (3.1%) | 3 (9.4%) | 8 (10.1%) | 42 (8.7%) |
| 2–5 | 52 (21.9%) | 9 (15.5%) | 4 (8.5%) | 6 (18.8%) | 5 (15.6%) | 12 (15.2%) | 88 (18.1%) | |
| 6–9 | 25 (10.5%) | – | 3 (6.4%) | 1 (3.1%) | 2 (6.3%) | 9 (11.4%) | 40 (8.2%) | |
| 10 or more | 58 (24.5%) | 14 (24.1%) | 7 (14.9%) | 10 (31.3%) | 15 (46.9%) | 18 (22.8%) | 122 (25.2%) | |
| Uncountable | 81 (34.2%) | 33 (56.9%) | 26 (55.3%) | 14 (43.8%) | 7 (21.9%) | 32 (40.5%) | 193 (39.7%) | |
| Portal vein | Patent | 234 (98.7%) | 58 (100%) | 43 (91.5%) | 32 (100%) | 30 (93.8%) | 75 (94.9%) | 472 (97.3%) |
| Segmental thrombosis | 3 (1.3%) | – | 3 (6.4%) | – | 1 (3.1%) | 2 (2.5%) | 9 (1.9%) | |
| Lobar thrombosis | – | – | – | – | 1 (3.1%) | 1 (1.3%) | 2 (0.4%) | |
| Main thrombosis | – | – | 1 (2.1%) | – | – | 1 (1.3%) | 2 (0.4%) | |
| Total tumour to liver percentage | Median | 8.9% | 20.8% | 7.8% | 6.6% | 10.7% | 10.9% | 10.5% |
| Q1, Q3 | 3.8%, 18.3% | 8.5%, 40.0% | 4.0%, 18.6% | 3.8%, 14.0% | 5.0%, 18.8% | 4.0%, 25.6% | 4.5%, 21.8% | |
| Missing | 40 (18.9%) | 17 (29.3%) | 18 (38.3%) | 6 (24.0%) | 12 (37.5%) | 12 (15.2%) | 105 (21.6%) |